Safety and clinical efficacy of TACE combined with camrelizumab and apatinib on middle-advanced hepatocellular carcinoma

ObjectiveTo study the clinical efficacy of transcatheter arterial chemoembolization (TACE) combined with camrelizumab and apatinib on middle-advanced hepatocellular carcinoma.

MethodsThe clinical data of 40 patients with middle-advanced hepatocellular carcinoma were retrospectively analyzed.The observation group (20 patients) was treated with TACE combined with camrelizumab and apatinib, and the control group (20 patients) was treated with TACE combined with apatinib.The short and long-term efficacy and adverse reactions were analyzed.

ResultsAfter 3 months of treatment, liver enhanced CT or MRI was reviewed.The objective remission rate of the observation group was 50.0% (10/20), which was higher than that of the control group (20.0% (4/20) (P < 0.05);the disease control rate in the observation group was 85.0% (17/20), which had no significant difference compared with 60.0% (12/20) in the control group (P>0.05).Follow up for 6-16 months, survival analysis showed that the average progression free survival, mean and median progression free survival in the observation group were 9.49 and 8.00 months, and those in the control group were 7.33 and 6.00 months, the difference between the two groups was statistically significant (P < 0.05).Common adverse reactions in patients included secondary hypertension, hand-foot syndrome, liver and kidney dysfunction, bone marrow suppression, cardiotoxicity, etc., which could be alleviated by reduction and symptomatic treatment.

ConclusionsTACE combined with camrelizumab and apatinib on middle-advanced hepatocellular carcinoma is safe and controllable, which can effectively prolong the survival period of patients, and it is worthy of clinical promotion.